Zymeworks/$ZYME
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Zymeworks
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
- Ticker
- $ZYME
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 231
- Headquarters
- Middletown, United States
- Website
- www.zymeworks.com
Zymeworks Metrics
BasicAdvanced
$2B
-
-$2.01
1.15
-
Price and volume
Market cap
$2B
Beta
1.15
52-week high
$31.34
52-week low
$16.00
Average daily volume
1.2M
Financial strength
Current ratio
6.316
Quick ratio
5.855
Long term debt to equity
0.158
Total debt to equity
0.199
Interest coverage (TTM)
-17.96%
Profitability
EBITDA (TTM)
-150.652
Gross margin (TTM)
-246.66%
Net profit margin (TTM)
-404.00%
Operating margin (TTM)
-418.99%
Effective tax rate (TTM)
0.92%
Revenue per employee (TTM)
$160,000
Management effectiveness
Return on assets (TTM)
-24.14%
Return on equity (TTM)
-72.31%
Valuation
Price to revenue (TTM)
57.557
Price to book
25.43
Price to tangible book (TTM)
30.34
Price to free cash flow (TTM)
-17.707
Free cash flow yield (TTM)
-5.65%
Free cash flow per share (TTM)
-1.616
Growth
Revenue change (TTM)
-69.78%
Earnings per share change (TTM)
105.54%
3-year revenue growth (CAGR)
-56.39%
3-year earnings per share growth (CAGR)
-10.27%
What the Analysts think about Zymeworks
Analyst ratings (Buy, Hold, Sell) for Zymeworks stock.
Analyst projections of the future price of Zymeworks stock.
Bulls say / Bears say
The FDA approved Ziihera for first-line HER2-positive gastro-oesophageal cancer in August, its second US indication. The approval triggers a $250 million payment to Zymeworks and leaves it eligible for royalties of up to 20% and further milestones. (Zymeworks)
Early Phase 1 results for ZW191 showed a 58.8% confirmed response rate in evaluable platinum-resistant ovarian cancer patients, with responses also seen in patients whose tumours had lower FRα expression. This offers a promising potential growth driver beyond the partnered zanidatamab programme. (Zymeworks)
The completed Theravance acquisition adds marketed products, including YUPELRI, and broadens Zymeworks’ sources of revenue beyond drug-development milestones. The company forecast 2026 revenue of $278–292 million and adjusted EBITDA of $114–128 million after the deal and Ziihera’s new approval. (FT.com)
The Theravance deal was partly funded by a $350 million note, with 75% of YUPELRI’s profit-share cash flows assigned to service it. That limits the cash Zymeworks can retain from a key asset while the financing is outstanding. (Zymeworks)
ZW191 remains an early-stage candidate, and its Phase 1 data showed grade 3 or worse treatment-related events in 55% of patients; 20% stopped treatment because of adverse events. These safety findings could complicate later development or limit its eventual use. (Zymeworks)
Ziihera’s recurring commercial contribution was still modest in the second quarter: Zymeworks reported $1.8 million in royalties and $4.6 million in total revenue. A meaningful earnings contribution therefore depends on partner-led sales growth, which remains less proven than the approval and milestone payment. (Zymeworks)
Data summarised monthly by Lightyear AI. Last updated on 18 Oct 2026.
Zymeworks Financial Performance
Revenues and expenses
Zymeworks Earnings Performance
Company profitability
Upcoming events
No upcoming events
Zymeworks News
AllArticlesVideos
Funds containing Zymeworks
Fund name | Fund size | $ZYME weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.13% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.13% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.13% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.13% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.13% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.